Skip to main content

Haemonetics Corp

HAE
Exchange
NYSE
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000313143

No open-market purchases or sales by Haemonetics Corp insiders were filed in the last 90 days; 329 institutions reported holding it in 13F filings for Q2 2026, worth $3.71B in total; no superinvestor holds it.

Holders of 5% or more of HAE

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Haemonetics Corp, largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Haemonetics Corp on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

4 Schedule 13D and 13G filings on Haemonetics Corp, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on HAE
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 12, 202510:34 AM ETWellington Management Group LLPand 2 others13G/A4.60%2.20M shares−0.80 ppfrom 5.40%Below 5%Jun 30, 2025SEC
May 14, 202510:47 AM ETT. Rowe Price Investment Management, Inc.13G/A4.40%2.20M shares–Below 5%Mar 31, 2025SEC
May 12, 202510:44 AM ETWellington Management Group LLPand 2 others13G/A5.40%2.69M shares–Mar 31, 2025SEC
Apr 4, 20254:24 PM ETCapital Research Global Investors13G/A3.10%1.58M shares–Below 5%Mar 31, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Haemonetics Corp shares.

No Form 144 notices for Haemonetics Corp are on file.